Drug Type Bispecific antibody |
Synonyms S-95029, S095029, SYM025 + [1] |
Target |
Action inhibitors, antagonists |
Mechanism HLA-E inhibitors(major histocompatibility complex, class I, E inhibitors), NKG2A antagonists(killer cell lectin like receptor C1 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Gastrooesophageal junction cancer | Phase 2 | United States | 13 Aug 2024 | |
| Gastrooesophageal junction cancer | Phase 2 | Japan | 13 Aug 2024 | |
| Gastrooesophageal junction cancer | Phase 2 | Australia | 13 Aug 2024 | |
| Gastrooesophageal junction cancer | Phase 2 | Austria | 13 Aug 2024 | |
| Gastrooesophageal junction cancer | Phase 2 | Belgium | 13 Aug 2024 | |
| Gastrooesophageal junction cancer | Phase 2 | Brazil | 13 Aug 2024 | |
| Gastrooesophageal junction cancer | Phase 2 | Canada | 13 Aug 2024 | |
| Gastrooesophageal junction cancer | Phase 2 | Denmark | 13 Aug 2024 | |
| Gastrooesophageal junction cancer | Phase 2 | France | 13 Aug 2024 | |
| Gastrooesophageal junction cancer | Phase 2 | Hungary | 13 Aug 2024 |
NCT05162755 (SITC2024) Manual | Phase 1 | 41 | bilgzpfwnv(mytxelstcs) = zcdsdwialq zveaqxeube (onuoiwlfjd ) View more | Positive | 05 Nov 2024 | ||
bilgzpfwnv(mytxelstcs) = aojyhzjlnd zveaqxeube (onuoiwlfjd ) | |||||||
Phase 1 | Solid tumor Last line | Second line | Third line | 41 | xunuaxcogo(esdrnxbvhm) = yqhqacvjic llzwzkvchb (udouzgfvjo ) View more | Positive | 05 Nov 2024 | ||
xunuaxcogo(esdrnxbvhm) = ygmfhskgcc llzwzkvchb (udouzgfvjo ) View more |






